Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets
D.R. Davies, Thale C. Jarvis(Crestone (United States))
Cited by 254
Related Papers
Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota
|Antimicrobial Agents and Chemotherapy|2019|38
Ribozymes as Tools for Therapeutic Target Validation in Arthritis
|The Journal of Immunology|2000|16